- Reaction score
- 1,712
Bavarian Nordic A/S, the only company with an approved vaccine for monkeypox, said it’s no longer certain it can meet demand as cases continue to rise across the world.
The Danish company is now exploring the possibility of outsourcing some of the production, including technology transfer to a US contract manufacturer, to meet accelerating demand.
“It’s a very dynamic market situation,” Rolf Sass Sorensen, a vice president at the firm, said by phone on Wednesday. “Demand keeps rising and it’s no longer certain that we can continue to meet the demand we’re facing even with the upgrade of our existing manufacturing site in Denmark.”
A move to outsourcing production would mark a shift for Bavarian which until now has said it could deliver on all orders from its Danish facility.
It also previously said a technology transfer to a third-party producer — which would allow bulk production of the vaccine rather than just ‘fill-finish’ where the doses are put into vials and packaging — would be too cumbersome, expensive and take too long.
The flare-up of the virus, which has spread to thousands of people in more than 70 countries in just a few months, was declared a public health emergency of international concern by the head of the World Health Organization last month.
The UK said earlier this week it’s facing a temporary shortage of the vaccine as it awaits further production of doses by the manufacturer.
The Danish company is now exploring the possibility of outsourcing some of the production, including technology transfer to a US contract manufacturer, to meet accelerating demand.
“It’s a very dynamic market situation,” Rolf Sass Sorensen, a vice president at the firm, said by phone on Wednesday. “Demand keeps rising and it’s no longer certain that we can continue to meet the demand we’re facing even with the upgrade of our existing manufacturing site in Denmark.”
A move to outsourcing production would mark a shift for Bavarian which until now has said it could deliver on all orders from its Danish facility.
It also previously said a technology transfer to a third-party producer — which would allow bulk production of the vaccine rather than just ‘fill-finish’ where the doses are put into vials and packaging — would be too cumbersome, expensive and take too long.
The flare-up of the virus, which has spread to thousands of people in more than 70 countries in just a few months, was declared a public health emergency of international concern by the head of the World Health Organization last month.
The UK said earlier this week it’s facing a temporary shortage of the vaccine as it awaits further production of doses by the manufacturer.
Monkeypox accelerating so fast the only approved vaccine maker admits it can't keep up with demand
The flare-up of the virus was declared a public health emergency of international concern by the head of the World Health Organization last month.
fortune.com